Migraine Disorders Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Single-Dose Pharmacokinetics of MK0462 in Subjects With Migraines Aged 6 to 17 Years
Verified date | February 2022 |
Source | Organon and Co |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A study to assess the safety, tolerability, and single dose pharmacokinetics of a marketed drug in pediatric subjects with migraines. After completion of a portion of the study (Panels A and B), a regulatory agency issued an amended request that the 12-17 year old age group studied should include a similar number of male and female subjects. Therefore, the study was amended to add an additional panel of subjects (Panel C) to ensure gender balance specifically in this age group.
Status | Completed |
Enrollment | 31 |
Est. completion date | September 17, 2010 |
Est. primary completion date | September 17, 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 17 Years |
Eligibility | Inclusion Criteria: - Panel A and B: Male and female subjects (non-smokers) ages 6 to 17 with a history of migraines - Panel C: Male subjects (non-smokers) ages 12 to 17 with a history of migraines - Subject has a history of migraine headaches, and is not experiencing a migraine on the day of study drug administration Exclusion Criteria: - Subject has no history of migraine headaches - Taking medications that are monoamine oxidase inhibitors (MAOI) and selective serotonin reuptake inhibitors (SSRI) - Subject has a condition which, in the opinion of the investigator, may interfere with optimal participation in the study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Organon and Co |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and Tolerability of Single Doses of Rizatriptan in Pediatric Migraineurs | All adverse experiences spontaneously reported by subject and/or observed by investigator and repeated clinical evaluation of physical examinations, vital signs, 12-lead ECG (electrocardiogram) and laboratory safety tests (hematology/blood chemistry/urinalysis) | 24 Hours | |
Secondary | Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan- Area Under the Curve (AUC(0-8)) | Preliminary pharmacokinetics data; Area Under the Curve (AUC(0-8)); i.e., area under the concentration-time plot | 24 Hours | |
Secondary | Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan - Maximum Concentration (Cmax) | Preliminary pharmacokinetics data; Maximum concentration (Cmax); i.e, highest concentration of drug achieved | 24 Hours | |
Secondary | Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan - Time to Maximum Concentration (Tmax) | Preliminary pharmacokinetics data; Time to maximum concentration (Tmax); i.e., amount of time required to reach maximum concentration | 24 Hours | |
Secondary | Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan - Apparent Half-life (Apparent t½) | Preliminary pharmacokinetics data; Apparent half-life (t½) | 24 Hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01432379 -
BOTOX® Prophylaxis in Patients With Chronic Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05048914 -
Migraine Abortive Treatment
|
||
Completed |
NCT03662295 -
Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
|
||
Completed |
NCT02766517 -
Biomarker Study in Participants With Migraine
|
Early Phase 1 | |
Completed |
NCT00963937 -
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
|
Phase 3 | |
Not yet recruiting |
NCT03632928 -
Day to Day Variation of Pressure Pain Threshold and Muscle Hardness
|
||
Completed |
NCT02559895 -
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
|
Phase 3 | |
Completed |
NCT01435941 -
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
|
N/A | |
Completed |
NCT00743015 -
Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks
|
Phase 1 | |
Completed |
NCT01376141 -
Drug Use Investigation for IMIGRAN Tablet
|
N/A | |
Completed |
NCT02183688 -
Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients
|
Phase 3 | |
Completed |
NCT06061588 -
"Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches"
|
N/A | |
Completed |
NCT03588364 -
The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine
|
N/A | |
Completed |
NCT04091321 -
Association Between Chronic Headache and Back Pain With Childbirth
|
||
Completed |
NCT00385008 -
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
|
Phase 3 | |
Active, not recruiting |
NCT05888298 -
Proximal and Distal Approach GON RFT in Migraine
|
N/A | |
Completed |
NCT03435185 -
Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients
|
N/A | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Completed |
NCT02565186 -
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
|
Phase 3 |